Developing Oral LT3 Therapy for Heart Failure – HFrEF

Developing Oral LT3 Therapy for Heart Failure – HFrEF

Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF); Low T3 Syndrome
Interventions: Drug: Liothyronine; Other: Placebo
Sponsors: University of Pennsylvania; National Heart, Lung, and Blood Institute (NHLBI)
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 27, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments